Prognostic Value of Dynamic Measurable Residual Disease Monitoring by Multiflowcytometry in Elderly Patients With Nonintensively Treated Acute Myeloid Leukemia
- 5 January 2025
- journal article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 25 (6) , 440-448
Abstract
No abstract availableKeywords
Funding Information
- Shanghai Shenkang Hospital Development Center (SHDC2020CR6004, SHDC2020CR5002)
This publication has 26 references indexed in Scilit:
- Measurable residual disease monitoring in AML: Prospects for therapeutic decision‐making and new drug developmentAmerican Journal of Hematology, 2024
- Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?Blood Reviews, 2024
- Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an ELN‐DAVID expert panelAmerican Journal of Hematology, 2023
- Acute myeloid leukaemiaThe Lancet, 2023
- Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemiaAmerican Journal of Hematology, 2023
- Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and OutcomesJAMA Network Open, 2021
- Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid LeukemiaJAMA Oncology, 2020
- Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemiaBone Marrow Transplantation, 2016
- Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemiaCancer, 2016
- Guadecitabine for AML and MDS: hype or hope?The Lancet Oncology, 2015